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Previous retrospective study (1992 to 2000) performed in Spain showed that drug toxicity, viral hepatitis, and indeterminate etiology
were the most prevalent causes of acute liver failure (ALF). In the last decade, there is no information about ALF in our country.
For these reasons we analyze retrospectively, in a ten-year period (2000 to 2010), the presumed causes, clinical characteristics,
course, and outcome of ALF in a Spanish community. Causes of ALF were indeterminate in 4 patients (24%), acute hepatitis B
infection in 4 patients (24%), drug or toxic reactions in 4 patients (24%), including one case of acetaminophen overdose, followed
by miscellaneous causes. The overall short-term survival (6 weeks after admission) was 65%. Liver transplantation was performed
in 11 patients with a survival of 82%. Despite fulfilling criteria, 2 patients were not transplanted because of contraindications; they
both died. In summary, acute hepatitis B and indeterminate cause are still being the most frequent causes of ALF in our region,
and patients with ALF have an excellent chance of survival after emergency liver transplantation. Acetaminophen overdose still
represents a very rare cause of ALF in our community.
1. Introduction
Acute liver failure (ALF) is a clinical syndrome, inwhich there
is an acute insult in a patient without a known preexisting
liver disease that leads to a rapid loss of liver function, charac-
terizedmainly by hepatic encephalopathy (HE), jaundice and
coagulopathy [1]. The prognosis of these patients was very
poor until the introduction of liver transplantation (LT) for
the treatment of this disease in the last decades, improving
their survival significantly [1, 2]. Current results of LT are
very good considering the natural history of the disease, the
multiorgan involvement, the emergency context, and the lack
of other effective therapies [3].
An important aspect of ALF that needs further clari-
fication is the varying composition of ALF causes among
different geographic regions [2, 4]. One retrospective study
from Spain summarized 267 ALF cases observed from 1992
to 2000 [5]. Our center participated in this study and
drug toxicity, viral hepatitis and indeterminate etiology were
the most prevalent causes of ALF [5]. In the last decade,
there are no published studies about ALF in our country.
For that reason, in our hospital, we decided to determine
retrospectively if in the last ten years there have been changes
in the etiology, clinical course, and outcome in patients with
ALF.
2. Patients and Methods
2.1. Enrollment of Patients andDefinitions of SevereAcute Liver
Injury and Acute Liver Failure. A retrospective, longitudinal
study was carried out at Marqués de Valdecilla University
Hospital (Santander, Spain). The hospital medical records
of patients who underwent the diagnosis of acute hepatitis
between January 2000 andDecember 2010were reviewed and
validated manually. Severe acute liver injury was defined as
acute (<12 weeks) liver dysfunction leading to an interna-
tional normalized ratio >1.5, but without documented level
of HE. Overt ALF was defined as evidence of coagulation
abnormality, usually an international normalized ratio ≥1.5,
and any degree of mental alteration (HE) in a patient without
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preexisting cirrhosis and with an illness of <26 weeks of
duration [3].
ALF was classified as fulminant when HE appeared
within the first two weeks after the onset of jaundice and as
subfulminant when appearing between weeks 3 and 8 [2]. In
addition, patients were also classified according to O’Grady
classification as having hyperacute, acute, or subacute impair-
ment [6].
2.2. Patient Collective and Parameter Evaluation. Themedical
records of these patients were searched after institutional
review board approval was obtained for the following data
fields: demographic features, date of diagnosis, suspected
cause of ALF, exposed to an NSAIDs or OTC, extra hepatic
complications during the admission; such as hypoglycemia,
infections, gastrointestinal bleeding, renal failure, and cere-
bral edema; grade of HE, date of transplantation, time in
waiting list, and contraindication for transplantation. Short-
term outcomes including survival with or without LT (spon-
taneous survival) and death were determined at 6 weeks after
study admission. Long-term survival (one-year survival) in
transplanted patients was reviewed.
In all patients, ALF etiologies were based on accepted
diagnostic criteria including clinical history, laboratory val-
ues, imaging studies, and subsequent pathological examina-
tion of liver explants consistent with massive or submassive
necrosis. ALFwas considered to be indeterminatewhen clini-
cal laboratory evaluations (including toxicological screening,
serological markers for viral hepatitis A, B, C, D, E, autoanti-
bodies, andmetabolic asWilson disease) and imaging studies
were inconclusive. Hepatic encephalopathy was graded on
a standard scale of 1–4 as described previously [7]. King’s
College criteria and Clichy’s criteria were determined as
described [2, 8, 9]. Cerebral edema was diagnosed by clinical
and imaging data. No patient was monitored for intracranial
pressure. All patients were treated similarly with standard
supportive treatment and strict monitoring in the ward, or
if required in the intensive care unit.
2.3. Statistical Analysis. The results were analyzed with the
SPSS 15.0 computer software package (Statistical Package for
Social Sciences, Inc., Chicago. IL) Continuous variables were
summarized as means or as medians and ranges. Categorical
variables were compared with the chi-square test and Fisher’s
exact test.
3. Results
Our hospital has been a tertiary academic center with experi-
ence in LT since 1990, and we are the hospital of reference for
LT for two autonomous community (Cantabria and LaRioja),
covering a population of one million inhabitants.
3.1. Study Population. During the study period (January 1,
2000 to December 31, 2010), 56 patients were admitted in
our institution with the diagnosis of “acute hepatitis” with
or without coagulopathy and/or HE. From these patients,
24 patients had a mild acute hepatitis, 15 patients severe
acute liver injury, and only 17 patients met criteria for ALF
(Figure 1). We are aware that the retrospective design of our
study could be a pitfall when calculating the incidence of the
disease.
3.2. Demographic Characteristics and Clinical Data. All
patients were Spanish.Of the 17 patients with ALF, 11 (65%)
werewomen.Themedian age of the groupwas 45 years (range
17 to 87 years) with 35% of patients younger than 40 years at
presentation; women were younger than men (with a mean
age of 40 versus 53 years, resp.).
At presentation, the absence of HE was the most frequent
finding (58%), with only one patient (6%) presenting deep
coma (grade IV HE), although this relation reversed during
followup (35% of patients developed grade IV, whereas no
patients remain without HE). The mean interval from onset
of symptoms to HE was 18 days (range 1–84 days).
According to Bernau classification, 76% (13 patients) had
a fulminant, and 24% (4 patients) had a subfulminant liver
failure. On the other hand, according to, O’ Grady, 53% (9
patients) were hyperacute, 24% were acute (4 patients), and
24% (4 patients) were subacute liver failure (Table 1).
3.3. Causes of ALF. Figure 2 andTable 1 display the presumed
causes of ALF and the outcome data for all these patients.
No patients were exposed to an NSAID or OTC within 30
days before the onset of clinical symptoms. Acute hepatitis
B and indeterminate causes were the most frequent causes of
ALF, accounting for eight patients. Among these eight, four of
them (24%) had acute hepatitis B, and the other four (24%)
had indeterminate causes.
Drug or toxic reactions were responsible for four
cases (24%) of ALF: one case of ecstasy/N-methyl-3,4-
methylenedioxyamphetamine (MDMA), one case of antitu-
berculosis drug induced hepatotoxicity, one case of antian-
drogen therapy for prostate cancer, and one case of
acetaminophen overdose with suicidal intent.
Finally, there was a miscellaneous group of five patients
(29%), including two cases of autoimmune hepatitis pre-
senting as ALF, one case of acute fatty liver pregnancy-
associated, one case of mushroom poisoning, and one case
of subfulminant hepatitis after biliopancreatic diversion for
morbid obesity.
3.4. Extrahepatic Complications. Five patients (29%) pre-
sented medical complications at admission. However, during
followup, the incidence of these complications increased
to twelve patients (71%). At admission, the most frequent
complication was renal failure. During followup, the most
frequent complications were renal failure (29%) followed by
hypoglycemia (23%), bacterial infection (12%), signs of cere-
bral edema (12%), gastrointestinal bleeding (12%), respiratory
failure (6%), and multiorgan failure (6%).
3.5. Outcome. The overall survival was 65% (11 of 17 patients)
at the end of the hospitalization (Figure 2). One patient
was considered to not fulfill criteria for emergency liver
transplantation (ELT) and survived without LT (Figure 2).
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56 patients with assumed acute
hepatitis were reported by our center
32 with documented primary severe
acute liver dysfunction (INR >1.5)
24 excluded because of mild liver
dysfunction (INR <1.5)
15 excluded with imminent ALF, for example
“severe acute liver injury” (sALI, INR
>   1.5, no HE)
17 included with overt ALF
(INR >1.5, documented HE)
Figure 1: Enrollment of study patients.
ALF patients, n = 17
No criteria for LT, n = 1 Criteria for LT, n = 16
Death on waiting
list, n = 2
Contraindications for
LT, n = 2
Live without LT, n = 1LT performed, n = 11
Alive six weeks after admission
n = 1 n = 0 n = 0 n = 9 n = 1
Figure 2: Outcome of 17 patients with acute liver failure.
From those who fulfill criteria for LT, 69% (11 of 16 patients)
were transplanted; in 12% (2 patients), transplantation was
contraindicated (one patient had prostate cancer, and the
other was an elderly patient, both patients died), 6% (1
patient) ALF resolved spontaneously, and 12% (2 patients)
died while waiting in transplantation list for cerebral edema
and multiorgan failure (Figure 2).
The overall survival in patients who were transplanted
was 82% (9 of 11 patients) at the end of the hospitalization.
Two patients died after transplantation, one because of
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Table 1: Clinical characteristics of patients according to O’Grady
classification.
Hyperacute LF Acute LF Subacute LF
Patients, 𝑛 9 4 4
Mean age (range),
y 49 (19–69) 41 (21–61) 38 (17–57)
Women, 𝑛 (%) 6 (67%) 2 (50%) 3 (75%)
Cause of ALF, 𝑛
Hepatitis B 2 2 0
Indeterminate 2 1 1
Drugs 2a 0 1b
Mushrooms 1 0 0
Acetaminophen 1 0 0
Pregnancy 1 0 0
Autoimmune 0 1 1
Other 0 0 1
Survived without




4 (44%) 3 (75%) 3 (75%)
Received
transplant, 𝑛 (%) 4 (44%) 3 (75%) 4 (100%)
One case of antituberculosis drug, and one case of antiandrogen therapya;
ecstasyb.
abdominal sepsis and the other because of biliary complica-
tions. Long-term survival rate was 82% in patients who were
transplanted.
The median time from waiting list to transplantation was
35 hours (range 7 to 120 hours), and median time to death
after admission was 22 days (range 2 to 35 days).
4. Discussion
ALF is the most common term applied to an unusual clinical
syndrome resulting from rapid loss in hepatocyte function
[1]. It occurs infrequently, affecting 2000 patients annually in
theUnited States, and comprises approximately seven percent
of liver transplants annually. The annual incidence does not
appear to be increasing or decreasing at this time [10], and
these data are similar in Europe countries [11, 12].The current
study analyzes the cause and outcome of ALF in the Spanish
community. It should be stressed that the retrospective design
of the study did not allow us to reach conclusive results.
ALF is a rare critical disease that occurs mainly in young
adults, approximately in fourth decade of life [10–12]. In our
study, we found that the mean age of presentation (45 years)
and female/male ratio (1.8/1) were similar to previous studies
[4, 5, 13–16]. In the present, it is uncertain why women are
more sensitive to ALF.
The etiology of this condition varies among the geo-
graphical area. In the United States [4, 17], Europe, and
United Kingdom [18] acetaminophen is the main cause of
ALF in contrast to India and other Asian countries, in
which viral hepatitis is the main cause [13, 14, 19, 20]. In
our study, we found an extraordinarily low incidence of
acetaminophen-related ALF, accounting for <6% of cases,
which is similar to the previous published data of the Spanish
population [5]. This figure (recently reviewed by Polson and
Lee) [21] strongly contrasts with the recent experience in
most Western countries, such as the United Kingdom [18],
Ireland, the United States [4], Sweden, and Denmark. This
might be due to underestimation of acetaminophen as a
cause of ALF because of possible inaccurate retrospective
data acquisition and lack of proper history-taking concerning
acetaminophen ingestion [22]. It has been shown that half of
acetaminophen overdoses are apparently unintentional [23]
and that acetaminophen toxicity is in fact causing many
cases of ALF not attributed to the drug without specific
testing [24]. In addition, the French experience indicated that
acetaminophen overdose causing ALF has been progressively
increasing in the last years, but this has not occur in Spain, at
least in our experience [25].
Two causes of ALF account for approximately half of the
patients in our study: the first is so-called indeterminate, that
accounts for approximately one third of ALF, as shown in
Table 1, which is almost similar to the Spanish and Argen-
tinean experience [5, 26]. Recently, the US ALF Study Group
has described that acetaminophen adducts were detected in
serum in some cases of indeterminate causes; thus, these ALF
cases could be classified due to this compound [24]. There-
fore, it could be argued that some of our cases were in fact due
to acetaminophen, although ingestion of this drug was not
detected. In the US study, patients in whom acetaminophen
adducts were detected showed hyperacute courses, with high
serum amine transferase (ALT) levels similar to classical
acetaminophen overdose. Our experience indicated that the
majority of cases considered indeterminate with hyperacute
courses makes the ingestion of acetaminophen possible.
The secondmain cause of ALF in our series was fulminate
hepatitis B virus infection, a figure that is similar to the
previous Spanish experience [5]. The universal vaccination
against this agent that started more than two decades ago in
Spain should decrease hepatitis B virus infections. However,
in our community, this programwas introduced later in 1996.
We think that this late introduction of the immunization
program could explain our findings. Nonetheless, since 2006
we have not had any new cases of acute hepatitis B liver
failure, leading us to think that the universal vaccination
program is accomplishing its objective, and maybe in the
following years our incidence of acute hepatitis B liver failure
can be reduced and be similar to that of developed countries.
Most patients in our study showed low grades of HE;
half of the cases arrived at our hospital with grade 0. This
observation was probably caused by the campaign in our
community that promotes early referral to our active liver
transplant program in our hospital.
Emergency liver transplantation (ELT) has been per-
formed in 65% of our patients with ALF, which is the highest
percentage amongWestern countries [27], reflecting the best
graft availability and the small number of acetaminophen
ingestion cases, since this etiology has the best prognosis
making transplant unnecessary [27]. The rapid access to ELT
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in Spain also accounts for the lowest risk of death while on
the waiting list. In the US ALF Study, 30% of patients listed
dead awaiting a graft; whereas, in Spain only 4% of the overall
series and 7%of those listed dead [5, 27], and 51.5%of theALF
patients were transplanted within 24 hours [5].
The survival of patients with ALF has changed dramat-
ically since the introduction of ELT. Before transplantation
era, mortality was very high, with survival rates without
ELT ranging from 13%–18% [16, 28, 29]. Nowadays, overall
survival is between 50%–70%, short-term survival after ELT
70%–80% and one-year rates survival is 79% according
to some series [4, 5, 10, 11, 15, 27]. In our study, overall
survival, short-term, and one-year rates survival after ELT
were similar.
In summary, we find that acute hepatitis B and indetermi-
nate cause are still being the most frequent causes of ALF in
our community and that patients with ALF have good chance
of survival with transplantation.
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